Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States.
Conclusion: SOF/VEL followed by SOF/VEL/VOX leads to comparable cure rates in the overall CHC population relative to the GLE/PIB treatment pathway. Based on wholesale acquisition prices, the SOF/VEL treatment pathway led to lower lifetime costs.
PMID: 31204882 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Clinical Trials | Health Management | Hepatitis | Hepatitis C | International Medicine & Public Health | Liver | Liver Disease | Nutrition | Study | Urology & Nephrology | USA Health | WHO